Highest-materiality recent filing
Pediatrix Q1 GAAP EPS $0.36, Adj. EPS $0.44; revenue $476M, beat expectations
Net revenue $476.2M, up 4% YoY from $458.4M; same-unit revenue grew 2.8%.
Pediatrix Q4 EPS $0.40; Adj. EPS $0.50; guides 2026 EBITDA $280-300M
Net revenue $494M, down slightly YoY; same-unit revenue up 4.0%.
Pediatrix Q3 EPS $0.84, revenue $493M; raises FY2025 Adj. EBITDA outlook to $270-290M
Net income $71.7M ($0.84/share) vs $19.4M ($0.23) year ago; adjusted EPS $0.67 vs $0.44.
Pediatrix Q2 EPS $0.46, Adjusted $0.53; raises FY 2025 EBITDA guidance to $245-255M
Net revenue $469M; net income $39M vs. loss of $153M a year ago due to non-cash impairment.
Pediatrix Q1 adjusted EPS $0.33; raises FY2025 EBITDA guidance to $220-240M
Net revenue $458M, down 7% YoY due to dispositions; same-unit revenue grew 6.2% on improved payor mix and volume.
Pediatrix Q4 net income $30M, Adjusted EPS $0.51, revenue up to $502M
GAAP EPS $0.36 (vs $1.50 loss Q4 2023); Adjusted EPS $0.51 (vs $0.32).
Mark S. Ordan appointed CEO of Pediatrix Medical Group effective Jan 12, 2025
Mark Ordan, 65, appointed CEO; he was CEO from 2020-2022 and most recently Executive Chair, succeeding Dr. Swift.
Pediatrix appoints Mark Ordan as CEO, expects 2024 adjusted EBITDA to exceed $215M guidance
Mark S. Ordan returns as CEO effective immediately, succeeding James D. Swift who will assist transition.
Pediatrix Q3 adjusted EPS $0.44, revenue $511M; reaffirms FY 2024 EBITDA guidance $205-215M
Net revenue $511M, up from $506.6M YoY; same-unit revenue grew 5.2% (reimbursement +3.4%, volume +1.8%).
Q2 net loss $153M ($1.84 loss per share) vs net income $28.3M ($0.34 EPS) in Q2 2023, driven by $192.9M impairment.
Company exiting office-based practices and primary/urgent care by end of 2024.
Pediatrix Medical Q1 GAAP EPS $0.05 vs $0.17 YoY; revenue up slightly to $495M
Net revenue $495M vs $491M YoY; same-unit revenue up 2.3%.
appointed Mr. Mark S. Ordan to serve as the Company’s Chief Executive Officer and principal executive officer, succeeding Dr. James D. Swift.
succeeding Dr. James D. Swift.
Mr. Richards’ transition from his role as Executive Vice President, CFO and Treasurer is a termination without “Cause” pursuant to that certain Amended and Restated Employment Agreement
On August 6, 2024, the Company announced that its board of directors (the “Board”) has appointed Ms. Kasandra Rossi, who currently serves as the Company’s Senior Vice President, Financial Reporting and Assistant Treasurer, to succeed Mr. C. Marc Richards as Executive Vice President, Chief Financial Officer (“CFO”) and Treasurer of the Company.
the Company announced that Curtis B. Pickert, M.D. has transitioned from his role as the Company’s Executive Vice President, Chief Operating Officer and will now serve as Pediatrix’s Executive Vice President, Chief Physician Executive, effective as of August 1, 2024.
The Company also announced that the Board has appointed Ms. Mary Ann E. Moore to serve as the Company’s Chief Administrative Officer, in addition to her existing roles as the Company’s Executive Vice President, General Counsel and Secretary, effective as of August 1, 2024.
On June 17, 2024, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), notified Mr. Lee. A Wood that the Company was eliminating the role of Executive Vice President, National and Market Operations, effective as of July 5, 2024 (the “Effective Date”), as part of the Company’s previously announced continued focus on operating efficiency.
Max materiality 0.80 · Median 0.62 · Most common event earnings